In Regulatory First, Myeloma Drug Approved Based on MRD Negativity.

Published in

Cancer discovery. Pages OF1. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

The FDA has approved iberdomide for multiple myeloma based on minimal residual disease negativity, marking a first for the disease. The drug also ushers in a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.

PMID:
42627098
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.